PMS-METOPROLOL-L TABLET
Země: Kanada
Jazyk: angličtina
Zdroj: Health Canada
Charakteristika produktu
(SPC)
24-09-2020
Některé dokumenty pro tento produkt momentálně nejsou k dispozici, můžete poslat požadavek našemu zákaznickému servisu a my vás upozorníme, jakmile je dokážeme získat.
Poslat žádost.
Poslat žádost.
Aktivní složka:
METOPROLOL TARTRATE
Dostupné s:
PHARMASCIENCE INC
ATC kód:
C07AB02
INN (Mezinárodní Name):
METOPROLOL
Dávkování:
100MG
Léková forma:
TABLET
Složení:
METOPROLOL TARTRATE 100MG
Podání:
ORAL
Jednotky v balení:
100/500/1000
Druh předpisu:
Prescription
Terapeutické oblasti:
BETA-ADRENERGIC BLOCKING AGENTS
Přehled produktů:
Active ingredient group (AIG) number: 0111923003; AHFS:
Stav Autorizace:
APPROVED
Datum autorizace:
1997-03-10
Charakteristika produktu
PRODUCT MONOGRAPH
PR
PMS-METOPROLOL-L
Metoprolol Tartrate Tablets, USP
25 mg, 50 mg and 100 mg
Β-ADRENERGIC RECEPTOR BLOCKING AGENT
PHARMASCIENCE INC.
6111 Royalmount Ave., Suite 100
Montréal, Canada
H4P 2T4
DATE OF REVISION:
September 24, 2020
www.pharmascience.com
SUBMISSION CONTROL NO: 240530
_pms-METOPROLOL-L Product Monograph _
_Page 2 of 39_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
..................................................................................................11
DRUG INTERACTIONS
..................................................................................................13
DOSAGE AND ADMINISTRATION
..............................................................................17
OVERDOSAGE
................................................................................................................20
ACTION AND CLINICAL PHARMACOLOGY
............................................................21
STORAGE AND STABILITY
..........................................................................................24
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................25
PART II: SCIENTIFIC INFORMATION
...............................................................................26
PHARMACEUTICAL INFORMATION
..........................................................................26
DETAILED PHARMACOLOGY
.....................................................................................27
TOXICOLOGY
...............................
Přečtěte si celý dokument
